ABIVAX
€83.50Change from previous close: −0.77%Absolute change: −€0.65
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 462 | 547 | 584 | 652 | 120 | — |
| Current assets | 428 | 513 | 551 | 619 | 86.1 | — |
| Cash and equivalents | 388 | 477 | 517 | 590 | 60.9 | — |
| Short-term investments | 22.7 | 14.1 | 13.7 | — | — | — |
| Receivables | 12.4 | 10.8 | 10.5 | 19.7 | 14.7 | — |
| Net property, plant and equipment | 1.5 | 1.8 | 2.1 | 1.9 | 2.2 | — |
| Goodwill | 18.4 | 18.4 | 18.4 | 18.4 | 18.4 | — |
| Other intangible assets | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | — |
| Long-term investments | — | — | 0.0 | 0.1 | 0.1 | 0.1 |
| Current liabilities | 71.7 | 62.2 | 63.0 | 78.8 | 112 | — |
| Accounts payable | 18.3 | 10.0 | 37.6 | 14.4 | 36.1 | — |
| Long-term debt | — | — | — | 15.9 | 34.8 | 47.0 |
| Total debt | 1.2 | 1.4 | 1.9 | 45.9 | 84.6 | — |
| Total liabilities | 95.9 | 118 | 129 | 141 | 168 | — |
| Total equity (incl. minority) | 366 | 430 | 455 | 511 | -48.3 | — |
| Retained earnings | -865 | -764 | -738 | -670 | -529 | — |